Companies › Chongqing Precision Biotech
16 active drug programs in 28 registered trials: 27 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| pCAR-19B cells CD19-directed autologous CAR-T cell therapy | – | Phase 2 | Acute Lymphoblastic Leukemia | Dec 2028 |
| Anti-CD19 UCAR-T cells anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Dermatomyositis, Juvenile | Nov 2026 |
| PIC1 Injection CAR-T cell therapy | – | Phase 1 | Non-Hodgkin Lymphoma | Dec 2026 |
| BCMA targeted prime CAR-T cells anti-BCMA CAR-T cell therapy | BCMA | Phase 1 | Multiple Myeloma | Dec 2026 |
| CD19 and CD22 targeted prime CAR-T cells CAR-T cell therapy targeting CEA (CEACAM5) | CD19, CEACAM5 | Phase 1 | B-ALL; Advanced Lung Cancer; Systemic Lupus Erythematosus | Dec 2026 |
| CD70 CAR-T cells anti-CD70 CAR-T cell therapy | CD70 | Phase 1 | Ovarian Cancer; Metastatic Tumor | Dec 2026 |
| CEA-targeted CAR-T cells anti-CEA chimeric antigen receptor T cell therapy | CEACAM5 | Phase 1 | Gastric Cancer; Colorectal Cancer; Lung Cancer; Peritoneal Metastases From Colorectal Cancer … | Dec 2026 |
| MC-1-50 CD19-targeted CAR-T cell therapy | CD19 | Phase 1 | B Cell Lymphoma; Systemic Lupus Erythematosus (SLE) | Dec 2026 |
| Anti-CD5 CAR NK cells anti-CD5 CAR-NK cell therapy | CD5 | Phase 1 | T-ALL/Lymphoma | Mar 2027 |
| Anti-CD123 CAR NK cells anti-CD123 CAR-NK cells | CD123 | Phase 1 | AML (Acute Myeloid Leukemia) | Jun 2027 |
| CD19-targeted CAR-T CAR-T cell therapy targeting CD19 | CD19 | Phase 1 | Juvenile Dermatomyositis | Jul 2027 |
| Invivo CAR-T CAR-T cell therapy | – | Phase 1 | B-Acute Lymphoblastic Leukemia | Dec 2027 |
| PTOC1 CD19-targeted CAR-T cell therapy | CD19 | Phase 1 | Systemic Lupus Erythematosus | Apr 2028 |
| PICX Injection In vivo CAR-T cell therapy | – | Phase 1 | Relapsed or Refractory Multiple Myeloma (RRMM) | Apr 2028 |
| BCMA/CD70 CAR-T cells Dual-targeted CAR-T cell therapy against BCMA and CD70 | TNFRSF17, CD70 | Phase 1 | Systemic Lupus Erythematosus | Aug 2028 |
| BCMA/CD70-targeted CAR-T Dual-targeted CAR-T cell therapy against BCMA and CD70 | BCMA, CD70 | Phase 1 | Juvenile Dermatomyositis (JDM) | Sep 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06686524 | Anti-CD19 UCAR-T cells | Phase 1 | Dermatomyositis, Juvenile | Immunology | Nov 2026 |
| NCT07456371 | PIC1 Injection | Phase 1 | Non-Hodgkin Lymphoma | Oncology | Dec 2026 |
| NCT06126406 | CEA-targeted CAR-T cells | Phase 1 | Gastric Cancer | Oncology | Dec 2026 |
| NCT06043466 | CEA-targeted CAR-T cells | Phase 1 | Colorectal Cancer | Oncology | Dec 2026 |
| NCT06180174 | MC-1-50 | Phase 1 | B Cell Lymphoma | Oncology | Dec 2026 |
| NCT04781634 | CD19 and CD22 targeted prime CAR-T cells | Phase 1 | B-ALL | Oncology | Dec 2026 |
| NCT06768151 | CD19 and CD22 targeted prime CAR-T cells | Phase 1 | Advanced Lung Cancer | Oncology | Dec 2026 |
| NCT04776330 | BCMA targeted prime CAR-T cells | Phase 1 | Multiple Myeloma | Oncology | Dec 2026 |
| NCT04271644 | BCMA targeted prime CAR-T cells | Phase 1 | Multiple Myeloma | Oncology | Dec 2026 |
| NCT06215950 | CD70 CAR-T cells | Phase 1 | Ovarian Cancer | Oncology | Dec 2026 |
| NCT06909474 | Anti-CD5 CAR NK cells | Phase 1 | T-ALL/Lymphoma | Oncology | Mar 2027 |
| NCT05518253 | CD70 CAR-T cells | Phase 1 | Metastatic Tumor | Oncology | May 2027 |
| NCT07247396 | CEA-targeted CAR-T cells | Phase 1 | Peritoneal Metastases From Colorectal Cancer | Oncology | May 2027 |
| NCT06690827 | Anti-CD123 CAR NK cells | Phase 1 | AML (Acute Myeloid Leukemia) | Oncology | Jun 2027 |
| NCT06569472 | CD19-targeted CAR-T | Phase 1 | Juvenile Dermatomyositis | Immunology | Jul 2027 |
| NCT07239323 | Invivo CAR-T | Phase 1 | B-Acute Lymphoblastic Leukemia | Oncology | Dec 2027 |
| NCT06945523 | CD19 and CD22 targeted prime CAR-T cells | Phase 1 | Advanced Lung Cancer | Oncology | Dec 2027 |
| NCT06903117 | CD19 and CD22 targeted prime CAR-T cells | Phase 1 | Advanced Lung Cancer | Oncology | Dec 2027 |
| NCT06892145 | MC-1-50 | Phase 1 | Systemic Lupus Erythematosus (SLE) | Immunology | Feb 2028 |
| NCT06992583 | CD19 and CD22 targeted prime CAR-T cells | Phase 1 | Advanced Lung Cancer | Oncology | Feb 2028 |
| NCT07179692 | CEA-targeted CAR-T cells | Phase 1 | Lung Cancer | Oncology | Mar 2028 |
| NCT07403097 | PTOC1 | Phase 1 | Systemic Lupus Erythematosus | Immunology | Apr 2028 |
| NCT07715630 | PICX Injection | Phase 1 | Relapsed or Refractory Multiple Myeloma (RRMM) | Oncology | Apr 2028 |
| NCT07250386 | CEA-targeted CAR-T cells | Phase 1 | NSCLC (Advanced Non-small Cell Lung Cancer) | Oncology | Jun 2028 |
| NCT07318259 | BCMA/CD70 CAR-T cells | Phase 1 | Systemic Lupus Erythematosus | Immunology | Aug 2028 |
| NCT07331467 | CD19 and CD22 targeted prime CAR-T cells | Phase 1 | Systemic Lupus Erythematosus | Immunology | Aug 2028 |
| NCT07184450 | BCMA/CD70-targeted CAR-T | Phase 1 | Juvenile Dermatomyositis (JDM) | Immunology | Sep 2028 |
| NCT05334823 | pCAR-19B cells | Phase 2 | Acute Lymphoblastic Leukemia | Oncology | Dec 2028 |
iCell Gene Therapeutics Jiangsu Topcel-KH Pharmaceutical Hrain Biotechnology PersonGen BioTherapeutics (Suzhou) Hebei Senlang Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.